Tim Kittell retweeted
Today is a day filled with joy, hope, and celebration! ❤️ Bella has finally rung the bell, marking the end of her cancer journey. What an incredible victory! Her courage and strength are truly inspiring. Wishing her a beautiful future filled with good health, happiness, and countless smiles. Cancer-free and ready for brighter days ahead! 🎉❤️🙏
Tim Kittell retweeted
It's genuinely depressing being aware the whole world is essentially a criminal enterprise. Ignorance is truly bliss.
Tim Kittell retweeted
Does anyone else find it odd that $200 billion is spent on cancer research every single year...and the only thing to show for it is a 75% increase in cancer deaths since the 1990s?
Outstanding work, @DrPatrick and @ImmunityBio Every step forward in cancer research brings renewed hope to families. Together,let’s keep advancing innovation and fighting to save lives.
$IBRX Let’s work toward giving more families hope and protecting more lives.
#Anktiva #Biotech
Tim Kittell retweeted
Last week, we honored our Veterans. Now, we’re listening to what they shared about the challenges of accessing #NMIBC care.
A new ImmunityBio survey conducted by @HarrisPoll found that 63% of veterans with NMIBC have faced treatment barriers, including long appointment waits (35%) and difficulty coordinating VA and non-VA care (27%).
These statistics represent delays and uncertainty for people who've already given so much. Researching and working to expand treatment options for patients with NMIBC is part of how we're working to change that.
Explore the full survey results: immunitybio.com/new-u-s-surv…
Tim Kittell retweeted
At #SNO2026, Dr. Simon Khagi presented QUILT-3.078 in a rapid oral session, exploring the investigational combination of ANKTIVA® (N-803) + PD-L1 t-haNK cell therapy in recurrent glioblastoma.
Together, we’re advancing neuro-oncology research.
#Glioblastoma #NeuroOncology
Tim Kittell retweeted
ImmunityBio shared three announcements today:
· QUILT-2.005: ANKTIVA® plus BCG met the primary endpoint in Cohort A of the randomized BCG-naïve, high-grade NMIBC trial
· Israel Approval: ANKTIVA® plus BCG was approved for adults with BCG-unresponsive NMIBC with CIS, with or without papillary tumors
· Q3 2026 & Global Progress: Net product revenue reached $48.7 million, up 53% year over year, alongside U.S. label expansion and an additional global approval
Read the full releases for complete information and important disclosures:
immunitybio.com/news-and-eve…








